The impact of new technologies in cervical cancer screening: Results of the recruitment phase of a large randomised controlled trial from a public health perspective

✍ Scribed by Paolo Giorgi-Rossi; Nereo Segnan; Marco Zappa; Carlo Naldoni; Manuel Zorzi; Massimo Confortini; Monica Merito; Jack Cuzick; Guglielmo Ronco

• Publisher: John Wiley and Sons
• Year: 2007
• Tongue: French
• Weight: 90 KB
• Volume: 121
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.23055

✦ Synopsis

Abstract

The decision to introduce liquid‐based cytology (LBC) and HPV as screening tests involves criteria based on resource consumption. We used cross‐sectional data at recruitment from the NTCC trial [ISRCTN81678807] on 28,000 women aged 35–60, randomised to receive a conventional Pap test or LBC plus HPV. We computed the resources employed to detect a CIN2+ with different screening strategies. In order to result in the same overall cost per CIN2+ detected as screening by conventional cytology, the unit cost of LBC used alone should be less than that of a conventional Pap while its unit cost may be up to 20% higher if HPV‐triage for Atypical Squamous Cells of Undetermined Significance is applied together. With the same criterion the unit cost of HPV used alone may be about 20% higher than that of a Pap‐test using a 1 pg/ml cut‐off and over 40% higher using a 10 pg/ml cut‐off. If HPV testing is applied with cytology‐triage, a single HPV test may cost 20–30% more than a conventional Pap to result in the same overall cost per CIN2+ detected. © 2007 Wiley‐Liss, Inc.